Evolving Strategies for Target Selection for Antibody-Drug Conjugates (Q38920359)

7 September 2017

title

Evolving Strategies for Target Selection for Antibody-Drug Conjugates (English)

1 reference

7 September 2017

Marc Damelin

1 reference

7 September 2017

Wenyan Zhong

series ordinal

1 reference

7 September 2017

Jeremy Myers

series ordinal

1 reference

7 September 2017

Puja Sapra

series ordinal

1 reference

7 September 2017

publication date

15 January 2015

1 reference

7 September 2017

published in

Pharmaceutical Research

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

7 September 2017

page(s)

3494-3507

1 reference

Small targeted cytotoxics: current state and promises from DNA-encoded chemical libraries

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Maturing antibody-drug conjugate pipeline hits 30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Investigational antibody drug conjugates for solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

The Cancer Genome Atlas Pan-Cancer analysis project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

The Genotype-Tissue Expression (GTEx) project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

RNA-Seq: a revolutionary tool for transcriptomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Global quantification of mammalian gene expression control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

A draft map of the human proteome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

A novel reactive ester derivative of biotin with reduced membrane permeability for in vivo biotinylation experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Functional rafts in cell membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

The quantitative proteome of a human cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Caveolin-1-dependent beta1 integrin endocytosis is a critical regulator of fibronectin turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Control of intracellular trafficking of ICAM-1-targeted nanocarriers by endothelial Na+/H+ exchanger proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Integrin activation and internalization on soft ECM as a mechanism of induction of stem cell differentiation by ECM elasticity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Antibody-drug conjugate targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

An antibody–cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Pertuzumab protects the achilles' heel of trastuzumab--emtansine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Mutations and response to epidermal growth factor receptor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Antibody drug-conjugates targeting the tumor vasculature: Current and future developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Monoubiquitin carries a novel internalization signal that is appended to activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Antibody-drug conjugate target selection: critical factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

A 72 kD trophoblast glycoprotein defined by a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Isolation and characterization of 5T4, a tumour-associated antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Waif1/5T4 inhibits Wnt/β-catenin signaling and activates noncanonical Wnt pathways by modifying LRP6 subcellular localization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Kit K641E oncogene up-regulates Sprouty homolog 4 and trophoblast glycoprotein in interstitial cells of Cajal in a murine model of gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

CXCL12 receptor preference, signal transduction, biological response and the expression of 5T4 oncofoetal glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Site-specific antibody drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-015-1624-3

Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms

21 January 2018

1 reference

12 December 2020

5T4 oncofetal antigen expression in ovarian carcinoma

1 reference

12 December 2020

Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates

1 reference

12 December 2020

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature

1 reference

12 December 2020

Epithelial-mesenchymal transition events during human embryonic stem cell differentiation

1 reference

12 December 2020

High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate.

1 reference

12 December 2020

Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer

1 reference

12 December 2020

10.1007/S11095-015-1624-3

Identifiers

DOI

1 reference

release_icj4bd5ffvgfnoroknixd5ctya

7 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/icj4bd5ffvgfnoroknixd5ctya

24 November 2022

mapped directly with Wikidata item

1 reference